| Literature DB >> 34479552 |
Yankai Dong1, Bo Tao2, Xing Xue1, Caixia Feng1, Yating Ren1, Hengyu Ma1, Junli Zhang1, Yufang Si1, Sisi Zhang1, Si Liu1, Hui Li3, Jiahao Zhou1, Ge Li1, Zhifei Wang1, Juanping Xie4, Zhongliang Zhu5.
Abstract
BACKGROUND: Increasing attention has been paid to the effect of Epimedium on the nervous system, particularly anti-depression function. In the present study, we applied network pharmacology to introduce a testable hypothesis on the multi-target mechanisms of Epicedium against depression.Entities:
Keywords: Epimedium; depression; molecular docking; network pharmacology; pathway analysis
Mesh:
Substances:
Year: 2021 PMID: 34479552 PMCID: PMC8417989 DOI: 10.1186/s12906-021-03389-w
Source DB: PubMed Journal: BMC Complement Med Ther ISSN: 2662-7671
Fig. 1Epimedium screening of bioactive compounds. (A) Venn diagram: 130 components (green section) and 23 bioactive components screened by two ADME-related models (blue section stands for the components of OB≥30%, yellow section stands for DL≥ 0.18). (B) Distributions of components in Epimedium
Basic information about the active compounds in Epimedium (OB≥30%, DL≥0.18)
| N.O. | MolId | MolName | OB(%) | DL |
|---|---|---|---|---|
| 1 | MOL001645 | Linoleyl acetate | 42.10 | 0.20 |
| 2 | MOL001792 | DFV | 32.76 | 0.18 |
| 3 | MOL003044 | Chryseriol | 35.85 | 0.27 |
| 4 | MOL003542 | 8-Isopentenyl-kaempferol | 38.04 | 0.39 |
| 5 | MOL000359 | sitosterol | 36.91 | 0.75 |
| 6 | MOL000422 | kaempferol | 41.88 | 0.24 |
| 7 | MOL004367 | olivil | 62.23 | 0.41 |
| 8 | MOL004373 | Anhydroicaritin | 45.41 | 0.44 |
| 9 | MOL004380 | C-Homoerythrinan, 1,6-didehydro-3,15,16-trimethoxy-, (3.beta.)- | 39.14 | 0.49 |
| 10 | MOL004382 | Yinyanghuo A | 56.96 | 0.77 |
| 11 | MOL004384 | Yinyanghuo C | 45.67 | 0.50 |
| 12 | MOL004388 | 6-hydroxy-11,12-dimethoxy-2,2-dimethyl-1,8-dioxo-2,3,4,8-tetrahydro-1H-isochromeno[3,4-hisoquinolin-2-ium | 60.64 | 0.66 |
| 13 | MOL004391 | 8-(3-methylbut-2-enyl)-2-phenyl-chromone | 48.54 | 0.25 |
| 14 | MOL004396 | 1,2-bis(4-hydroxy-3-methoxyphenyl)propan-1,3-diol | 52.31 | 0.22 |
| 15 | MOL004427 | Icariside A7 | 31.91 | 0.86 |
| 16 | MOL000006 | luteolin | 36.16 | 0.25 |
| 17 | MOL000622 | Magnograndiolide | 63.71 | 0.19 |
| 18 | MOL000098 | quercetin | 46.43 | 0.28 |
| 19 | MOL004386 | Yinyanghuo E | 51.63 | 0.55 |
Fig. 2Common-target network. (A). Mapping of Epimedium- and depression-related targets and the 53 common targets. (B). Construction of Epimedium component-target visual network. Blue node stands for Epimedium, yellow nodes stand for bioactive components, and red nodes stand for predicted targets. (C). Interaction network of Epimedium-related target proteins. The dark blue nodes represent the big hub nodes. The node size was proportional to the target degree in the network. (D). Interaction network of proteins related to the treatment of depression by Epimedium. The green nodes represent the big hub nodes. The node size was proportional to the target degree in the network
Information about potential antidepressant targets from Epimedium
| serial number | name | degree | serial number | name | degree |
|---|---|---|---|---|---|
| 1 | AKT1 | 41 | 27 | OPRM1 | 15 |
| 2 | IL6 | 38 | 28 | IGF2 | 14 |
| 3 | VEGFA | 34 | 29 | ADRB2 | 14 |
| 4 | EGF | 31 | 30 | DRD2 | 13 |
| 5 | IL1B | 29 | 31 | IRF1 | 13 |
| 6 | CCL2 | 29 | 32 | COL1A1 | 13 |
| 7 | MMP9 | 29 | 33 | SLC6A4 | 13 |
| 8 | PTGS2 | 28 | 34 | GJA1 | 13 |
| 9 | SERPINE1 | 25 | 35 | PLAT | 12 |
| 10 | MMP2 | 25 | 36 | HTR3A | 12 |
| 11 | PPARG | 25 | 37 | DPP4 | 12 |
| 12 | CCND1 | 24 | 38 | PRKCB | 11 |
| 13 | APP | 24 | 39 | ADRA2A | 11 |
| 14 | ICAM1 | 23 | 40 | DRD5 | 11 |
| 15 | ESR1 | 22 | 41 | DRD1 | 11 |
| 16 | IL4 | 21 | 42 | SLC6A3 | 9 |
| 17 | HMOX1 | 21 | 43 | ESR2 | 9 |
| 18 | HIF1A | 20 | 44 | ADRB1 | 9 |
| 19 | IL2 | 20 | 45 | SLC6A2 | 9 |
| 20 | CRP | 20 | 46 | MAOB | 9 |
| 21 | STAT1 | 19 | 47 | GRIA2 | 7 |
| 22 | NOS2 | 18 | 48 | CHRM2 | 7 |
| 23 | IL1A | 17 | 49 | PON1 | 7 |
| 24 | SOD1 | 17 | 50 | PPP3CA | 5 |
| 25 | AR | 16 | 51 | RASA1 | 4 |
| 26 | GSK3B | 15 | 52 | NR3C2 | 4 |
Fig. 3Enrichment of gene ontology (GO) and KEGG pathway of Epimedium in the treatment of depression. (A).Enriched GO terms for biological process (BP) of potential antidepressant targets from main active ingredients of Epimedium. (B). Enriched GO terms for the cellular component of potential antidepressant targets from main active ingredients of Epimedium.(C). Enriched GO terms for molecular function of potential antidepressant targets from main active ingredients of Epimedium. (D). Enriched KEGG pathways of potential antidepressant targets from main active ingredients of Epimedium
Fig. 5Binding mode of protein and different ligands.(A) Binding mode of IL6 with luteolin, quercetin, and kaempferol.(B) Binding mode of VEGFA with luteolin, quercetin, and kaempferol. (C) Binding mode of AKT1 with luteolin, quercetin, and kaempferol. (D) Binding mode of EGF with luteolin, quercetin, and kaempferol. Pink represents the amino acids that form electrostatic force, and green represents the amino acids that form van der Waals force
Fig. 42D and 3D structures of ligands. (A) 2D structure of kaempferol. (B) 2D structure of luteolin. (C) 2D structure of quercetin. (D) 3D structure of kaempferol. (E) 3D structure of luteolin. (F) 3D structure of quercetin
Binding energy (kcal/mol) and RMSD of three components of Epimedium and target proteins
| parameter | Estimated Free Energy of Binding | RMSD | ||||||
|---|---|---|---|---|---|---|---|---|
| receptor | IL6 | VEGFA | AKT1 | EGF | IL6 | VEGFA | AKT1 | EGF |
| ligand | ||||||||
| luteolin | -5.48 | -6.74 | -6.95 | -7.33 | 0.062 | 0.063 | 0.067 | 0.066 |
| quercetin | -5.2 | -7.31 | -6.95 | -6.3 | 1.165 | 1.166 | 1.17 | 1.17 |
| kaempferol | -5.9 | -6.85 | -6.82 | -6.49 | 0.064 | 0.066 | 0.069 | 0.069 |
| fluoxetine | -4.77 | -5.11 | -5.35 | -5.71 | 0.653 | 0.632 | 0.643 | 0.627 |
Interaction between ligands and target proteins
| Force | electrostatic force | van der Waals force | ||||||
|---|---|---|---|---|---|---|---|---|
| receptor | IL6 | VEGFA | AKT1 | EGF | IL6 | VEGFA | AKT1 | EGF |
| ligand | ||||||||
| luteolin | SER C:227、TRP C:225、ASN C:226、ASP C:221、PRO C:222、HIS C:223、SER E:55、ARG E:57、ALA E:105、CYS E:104、ARG E:103、SER E:103、ILE E:102、SER C:228、TYR E:52、TYR E:59 | CYS A: 104, HIS C: 8, Val C: 9, TYR A: 25, CYS A: 26, HIS A: 27, GLN A: 22, NLE C: 10 | HIS A: 207, TYR A: 263, SER A: 205, LYS A: 268, ASN A: 269, ASN A: 53, TRP A: 80, ASP A: 292, THR A: 211 | GLY A: 12, HIS A: 10, ASP A: 11, CYS A: 14, TYR A: 13, LEU A: 8, PRO A: 7, CYS A: 6, ASP A: 17 | TYR E: 59 | GLU A: 103, CYS A: 102, PRO A: 28, ARG A: 23 | GLN A: 79, LEU A: 264, ARG A: 206, LEU A: 210, MET A; 227, VAL A: 210 | GYS A: 20, VAL A: 19, GLY A: 18 |
| quercetin | CYS V: 104, ARG V: 57, SER V: 55, HIS D: 223, PRO D: 222, ASP D: 221, TRP D: 225, SER D: 227, TYR V: 52, PHE D: 229, SER D: 228, GLN A: 75, ILE V: 102, SER V: 101 | CYS A: 60, ASN A: 62, ASP A: 63, CYS A: 61, LYS B: 48, PHE B: 47, GLU A: 64, LYS A: 107, CYS A: 68, GLY A: 59 | GLN A: 59, ILE A: 186, LEU A: 78, ALS A: 58, CYS A: 60, CYS A: 77, GLN A: 79, ASN A: 53, SER A: 56 | CYS B: 14, GLY B: 18, ASP B: 17, GLY B: 12, ASP B: 11, LEU B: 8, PRO B: 7, CYS B: 20, TYR B: 13 | ASN D: 226, Tyr V: 59 | GLU A: 67, LEU a: 66, PRO B: 49, ILE B: 46 | / | SER B: 9, VALB: 19, HIS B: 10 |
| kaempferol | ARG V: 57, TYR V: 59, ARG V: 103, ALA V: 105, ILE V: 102, CYS V: 104, SER V: 101, SER D: 228, TYR V: 52, SER V: 55, SER D: 227, ASP D: 221, PRO D: 222, TRP D: 225, HIS D: 223 | TYR B: 25, CYS B: 26, VAL D: 9 ,HIS D:8,GLN B:22,CYS B:104,CYS B:102 | VAL A: 185, CYS A: 60, GLN A: 104, ASD A: 108, GLN A: 61, LEU A: 78, ARG A: 76, ILE A: 186 | ASP B: 11, CYS B: 120, GLY B: 12, ASP B: 17, GLY B: 18, CYSB: 14, LEU B: 15, TYR B: 13, PRO B: 7, LEU B: 8 | ASN D: 226 | NLE D:10, GLU B :103,HIS B :27, LYS B :101,PRO B:28 | VAL A: 83, LYS A: 111, CYS A: 77 | SER B: 9, VAL B: 19, HIS B: 10 |
| Fluoxetine( | ASP B:26, ARG B:30, LYS C:252, ASP C :253, GLU C:23, LYS B :27 | CYS B:102, HIS B:27, GLN B:22, CYS B:26 | ASN A:31, VAL A:106, THR A:105,ASP A:3 | ASP A:17, CYS A:20, CYS A:6,TYR A:13, ASP A :11,CYS A:14, GLY A:18, | SER E :30, ARG C :231, THR E:31, ARG B:182, LEU C :254, TYR E:27 | HIS D:8, VAL D:9, PRO B:28, TYR B :25, LYS B :101, ARG B :23, GLU B :103, NLE D:10, CYS B:104, | ASP A:32, VAL A;7, GLY A:109, VAL A:4, LEU A :110 | LEU A:15, LEU A:8, VAL A:19, GLY A :12, HIS A :16 |
"/" means no amino acid residues